Cyprumed
Private Company
Funding information not available
Overview
Cyprumed is a private, pre-revenue biotechnology company with a proprietary platform for oral delivery of peptides and BCS Class IV drugs. Its technology demonstrates superior oral bioavailability in large animal models and is designed for convenient tablet formulation, scalability, and regulatory compliance. The company has established significant validation through collaborations and a license agreement with top-tier pharmaceutical firms including MSD, Bayer, Boehringer Ingelheim, and Ferring.
Technology Platform
Proprietary oral drug delivery platforms for peptides (intestinal and gastric delivery) and BCS Class IV drugs (e.g., PROTACs). Focus on tablet formulations offering superior bioavailability, scalability, and room-temperature stability.
Opportunities
Risk Factors
Competitive Landscape
Cyprumed competes in the oral biologics delivery space against companies like Oramed Pharmaceuticals, Entera Bio, and Rani Therapeutics, as well as internal efforts at large pharmaceutical firms. Its differentiation lies in its specific focus on tablet-based formulations for peptides and BCS IV drugs, claimed superior bioavailability, and a partnership model validated by top-tier pharma collaborators.